The Relative Strength (RS) Rating for Supernus Pharmaceuticals climbed into a new percentile Wednesday, with a rise from 77 to 82.
IBD's proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Supernus Pharmaceuticals is now considered extended and out of buy range after clearing a 35.41 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Supernus Pharmaceuticals reported 0% earnings growth in the latest quarterly report. Revenue gains came in at 14%.
The company earns the No. 9 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
